Drug Name Erythromycin

Hydroxyzine is an antihistamine with anticholinergic (drying) and sedative properties that is used to treat allergic reactions. The body releases histamine during several types of allergic reactions and--to a lesser extent--during some viral infections, such as the common cold. When histamine binds to its receptors on cells, it causes the cells to release chemical messengers that lead to sneezing, itching, and increased mucus production.
On 23 October 2008, the European Medicines Agency (EMEA) issued a press release stating its Committee for Medical Products for Human Use (CHMP) had concluded the benefits of Acomplia no longer outweighed its risks, and subsequently recommended the product be suspended from the UK market. Sanofi-Aventis later released a press statement stating the drug had been suspended. Approval of the drug was officially withdrawn by the EMEA on 16 January 2009.

 

Erythromycin is a macrolide antibiotic that has an antimicrobial spectrum similar to or slightly wider than that of penicillin, and is often used for people who have an allergy to penicillins. For respiratory tract infections, it has better coverage of atypical organisms, including mycoplasma and Legionellosis.
Amoxicillin is susceptible to degradation by b-lactamase-producing bacteria, and so may be given with clavulanic acid to decrease its susceptibility.